MarketPulse

underwriting

8 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Wtw

Specialty Insurance Rates Tumble to 2020 Lows as Market Softening Accelerates

Specialty insurance rates declined faster than expected, retreating to 2020 pricing levels. WTW survey shows 75% of material classes experienced rate decreases.
WTWpremium pricingunderwriting
BenzingaBenzinga··Na

Hemab Therapeutics Prices $346.7M IPO as Blood Disorder Biotech Debuts on Nasdaq

Hemab Therapeutics raised $346.7M in upsized IPO, pricing 19.3M shares at $18 with full underwriter exercise.
COAGIPOclinical-stage
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Intellia Therapeutics Raises $180M in Stock Offering to Fuel CRISPR Pipeline

Intellia Therapeutics raises $180M via stock offering at $10.75/share to advance CRISPR gene-editing therapies, with lead underwriters Jefferies, Goldman Sachs, Citigroup.
REGNNTLApublic offeringcapital raise
BenzingaBenzinga··Na

Trevi Therapeutics Prices $150M Stock Offering as It Advances Chronic Cough Treatment

Trevi Therapeutics raises $150M via stock offering at $13/share to fund development of Haduvio for idiopathic pulmonary fibrosis-related cough.
TRVIstock offeringclinical-stage
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Allogene Therapeutics Raises $175M Via Stock Offering to Fund Clinical Pipeline

Allogene prices 87.5M shares at $2.00 each, raising $175M gross proceeds for clinical trials and R&D operations.
ALLOclinical trialspublic offering
The Motley FoolThe Motley Fool··Jennifer Saibil

Progressive Quietly Crushes S&P 500: A Decade of Disciplined Underwriting Pays Off

Progressive outperformed S&P 500 by 33% over a decade through superior underwriting discipline, now trading at just 10x earnings.
PGRvaluationearnings growth
BenzingaBenzinga··Shomik Sen Bhattacharjee

Musk's Bold Retail Strategy: SpaceX Eyes 30% IPO Allocation to Loyal Followers

SpaceX reportedly considers 30% retail IPO allocation, three times typical levels. Bank of America handles distribution for $1.75T valuation and $75B fundraising goal.
BACBACpBBACpEBACpKBACpL+15valuationElon Musk
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Dianthus Therapeutics Raises $625M in Upsized IPO Offering to Fund Pipeline Expansion

Dianthus Therapeutics prices $625M upsized offering at $81/share to fund drug development and commercial readiness. Closing expected March 12, 2026.
DNTHbiotechclinical-stage